amaranth

(redirected from Amarantus)
Also found in: Dictionary, Thesaurus, Encyclopedia.

am·a·ranth

, amaranthum (am'ă-ranth, am-ă-ran'thŭm), [C.I. 16185]
An azo dye; a soluble reddish-brown powder that turns magenta red in solution; used as a food, pharmaceutical, and cosmetic coloring agent, and occasionally in histology.
[G. amaranthon, a never-fading flower]

am·a·ranth

(am'ă-ranth)
A weed (Amaranthus) of widespread geographic distribution; some species are consumed as a foodstuff; its prolific ability to produce seed allows its use as a flour. Purported value both internally and externally (e.g., astringent).
Synonym(s): love-lies-bleeding, red cockscomb.
[G. amaranthon, a never-fading flower]
References in periodicals archive ?
Under the terms of the agreement, the virtual chief commercial officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation.
In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc.
As part of Amarantus' agreement with the Army, the service will allow its soldiers to enroll in clinical studies testing the skin substitute.
Commissiong, president and chief executive officer of Amarantus. "Advancing MANF, our first internally-discovered therapeutic product candidate, into human clinical studies will be a major advancement for the Company.
subsidiary and US-based biotechnology company Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings Inc (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, has appointed Brian E Harvey, MD PhD to its strategic advisory board, it was reported on Friday.
Amarantus BioScience and Anavex Life Sciences Corp.
Competition berween Phasolous vulgaris and Amarantus in different plant density.
The decision comes as Generex is focusing on its insulin spray product and a research collaboration with Amarantus BioSciences Inc.
Amarantus BioScience, a publicly traded biotechnology company, has received orphan drug designation for Eltoprazine from the US FDA, it was reported yesterday.